Skip to content
OpenCapital
Get started

Quest Diagnostics DGX Cash & Equivalents

Cash & Equivalents at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
$126M+24.8%
Labcorp Holdings logo
Labcorp HoldingsLH
$981.1M+166%
NeoGenomics logo
NeoGenomicsNEO
$146.14M-57.8%
Exagen Inc. logo
Exagen Inc.XGN
$21.71M+90.6%
Personalis, Inc. logo
Personalis, Inc.PSNL
$73.59M+3.7%
Sera Prognostics logo
Sera PrognosticsSERA
$4.18M-20.2%

Other financials

Income statement

See full
Revenue$2.9B+9.2%
Gross profit$942.0M+9.2%
Operating income$399.0M+15.3%
Net income$252.0M+14.5%
EPS (diluted)$2.24+15.5%

Balance sheet

See full
Total debt$6.4B-2.5%
Total equity$7.4B+6.3%
Total assets$16.7B+5.5%

Cash flow

See full
Operating cash flow$278.0M-11.5%
CapEx$114.0M-2.6%
Free cash flow$164.0M-16.8%

Valuation

See full
Market cap$23.46B+20.8%
Enterprise value$29.48B+15.7%
P/E22.9×+2.5×
P/S2.1×+0.2×

Profitability

See full
Gross margin33.2%+0.4pp
Operating margin14.3%+0.6pp
Net margin9.1%+0.2pp
FCF margin11.8%+1.4pp

Returns & leverage

See full
Return on equity14.3%+0.9pp
Debt / equity0.9×-0.1×
Current ratio1.2×-0.3×

Where this comes from

Reported directly by Quest Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Quest Diagnostics’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Quest Diagnostics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Quest Diagnostics's cash & equivalents?
Quest Diagnostics (DGX) reported cash & equivalents of $393M in Q1 2026.
How has Quest Diagnostics's cash & equivalents changed year-over-year?
Quest Diagnostics's cash & equivalents increased by 109.0% year-over-year, from $188M to $393M.
What is the long-term trend for Quest Diagnostics's cash & equivalents?
Over 5 years (2020 to 2025), Quest Diagnostics's cash & equivalents has grown at a -18.4% compound annual growth rate (CAGR), from $1.16B to $420M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.